Stage II Colon Cancer, Stage III Colon Cancer
Conditions
Keywords
stage II and stage III colon cancer survivors, who have completed curative treatment i.e., surgical resection and chemotherapy for their colon cancer
Brief summary
Despite the success of surgery and chemotherapy among people with colon cancer, 30-50% of patients develop recurrent disease. Physical activity has emerged as a potential lifestyle intervention to reduce cancer recurrence and improve survival among people with colon cancer (CC). This pilot study aims to identify the dose-response effects of aerobic exercise on molecular and cellular pathways associated with physical activity and CC outcomes among patients with stage II and III CC.
Interventions
OTHERExercise
Sponsors
Abramson Cancer Center at Penn Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Intervention model description
exercise
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. histologically confirmed TNM stage II-III CC; 2. completed surgical resection and adjuvant chemotherapy (if applicable) within 1-24 months before entering the study; 3. ≤120 min/wk of self-reported moderate or vigorous intensity physical activity using the Paffenbarger physical activity questionnaire; 4. age ≥18 years; 5. written physician approval; 6. no additional surgery planned within the 6-month intervention (including colostomy reversal); 7. ability to walk unaided for 6-minutes; 8. no contraindications to exercise using the PA readiness questionnaire (PAR-Q), unless physician approves participation with specific knowledge of this contraindication.
Exclusion criteria
1. history of another primary invasive cancer (other than non-melanoma skin-cancer); 2. evidence of metastatic CC (i.e., TNM M1); 3. planning to receive any additional adjuvant chemotherapy; 4. pregnant or breast feeding; 5. unable to provide baseline blood sample; 6. cardiac conditions, including the following: 1. myocardial infarction or coronary revascularization procedure within prior 3 months; 2. uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥100 mmHg); 3. high-risk or uncontrolled arrhythmias; 4. clinically significant valvular disease; 5. decompensated heart failure; 6. known aortic aneurysm; 7. any other condition that may impede testing of the study hypothesis or make it unsafe to engage in the exercise program (determined by the investigative team).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The biological efficacy of aerobic exercise on soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular adhesion molecule-1 (sVCAM-1) prognostic biomarkers. | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Exercise adherence, quantified as the percentage of total dose completed relative to the total dose prescribed during the six-month study; | 6 months |
| Visceral adipose tissue and anthropometric measures at baseline and six-months; | 6 months |
| Fasting insulin measured at baseline and six-months; | six months |
| Circulating tumor cells measured at baseline and six-months. | six months |
Countries
United States
Outcome results
None listed